Lördag 28 December | 07:00:47 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-04-25 N/A Årsstämma
2025-02-26 N/A Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av analytiska program. Produktportföljen är bred och inkluderar exempelvis program för intern uppföljning, process- samt systemhantering. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster inom arbetsområdet. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Magle Chemoswed har sitt huvudkontor i Malmö.
2024-02-16 08:30:00

Magle Chemoswed Holding AB (publ), an established innovation-led healthcare group with proven growth through risk diversification and focus on high-value revenue streams, today publishes the interim report for the fourth quarter of 2023 and the full year 2023. In conjunction with the Q4 and Full Year 2023 report, the Board of Directors has proposed to pay a dividend of SEK 0.35 to the shareholders for the fiscal year 2023. The detailed dividend proposal will be put forward by the Board in connection with the notice of the Annual General Meeting which is then subject to approval from the Annual General Meeting taking place on the 25th of April 2024.

OCTOBER – DECEMBER 2023

• Net sales amounted to 57.4 MSEK (45.9).

• EBITDA equalled 9.3 MSEK (6.2).

• Operating profit (EBIT) is 5.9 MSEK (3.2).

• Profit after tax amounted to 4.1 MSEK (0.6).

• Earnings per share SEK 0,4 (0,1) per share

JANUARY – DECEMBER 2023

• Net sales amounted to 170.4 MSEK (145.7).

• EBITDA equalled 31.1 MSEK (25.8).

• Operating profit (EBIT) is 18.0 MSEK (12.8).

• Profit after tax amounted to 12.2 MSEK (9.1).

• Earnings per share SEK 1,1 (0,8) per share.

Justin Pierce, CEO of Magle Chemoswed Holding AB, commented, “The full year of 2023 marked another milestone in our journey of growth and innovation. With significant revenue growth, strategic expansions, and pioneering DSM products and pipeline, we’re setting new standards in healthcare.

EVENTS DURING THE REPORTING PERIOD

• Automated fill and finish line investment closed.

• Barbara Willkomm appointed as the Director of Human Resources.

• A subsidiary, Magle Chemoswed LLC, has been registered in Delaware, USA.

EVENTS AFTER THE REPORTING PERIOD

• Initiated U.S. registration process for EmboCept®S

• The Board of Directors proposes a dividend of 0,35 SEK per share for the fiscal year.

• The detailed dividend proposal will be published in connection with the notice of the Annual General Meeting.

The full report can be downloaded at https://maglegroup.com/financial-reports/